Barchart.com's Chart of the Day - Immunomedics
Related Stocks
 IMMU - Immunomedics Inc
SymLastChgPct
IMMU11.58-0.17-1.45%
The Chart of the Day belongs to Immunomedics (IMMU).  I found the biomedical stock by using Barchart to sort today's Top Stocks to Ownlist first for the highest Weighted, then again for technical buy signals of 80% or more.  Since the Trend Spotter signaled a buy on 8/22 the stock gained 9.61%.

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or `naked` form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.


The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

  • 88% technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 7 new highs and up 20.00% in the last month
  • Relative Strength Index 69.89%
  • Technical support level at 10.00
  • Recently traded at 10.38 with a 50 day moving average of 8.62
Fundamental factors:
  • Market Cap $1.19 billion
  • Revenue expected to grow 673.60% this year and another 82.00% next year
  • Earnings estimated to increase 62.60% this year and an additional 47.30% next year
  • Wall Street analysts issued 3 strong buy recommendations on the stock